Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Core Viewpoint - Corcept Therapeutics faces a class action lawsuit following a significant drop in stock price after the FDA declined to approve its New Drug Application for relacorilant, citing insufficient evidence of effectiveness [2][3]. Company Overview - Corcept Therapeutics Incorporated (NASDAQ: CORT) is involved in the development of treatments for conditions related to cortisol, specifically hypercortisolism [1]. FDA Response - On December 31, 2025, the FDA issued a Complete Response Letter (CRL) for Corcept's NDA for relacorilant, stating it could not make a favorable benefit-risk assessment without additional evidence [2]. - The stock price of Corcept fell by $35.40 per share, or 50.42%, closing at $34.80 on the same day [2]. Class Action Details - The class action lawsuit alleges that Corcept made materially false and misleading statements regarding the adequacy of its clinical development program and the FDA's concerns about relacorilant [3]. - Specific allegations include failure to disclose the FDA's concerns about the pivotal "GRACE" trial and expectations of significant review issues if the NDA was submitted [3]. Legal Proceedings - Investors who purchased Corcept common stock during the Class Period (October 31, 2024, to December 30, 2025) have until April 21, 2026, to file a lead plaintiff motion in the class action [1][4].